| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$98.6M | ROE | −31.41% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its product candidates include NGN-401, an adeno-associated virus 9-packaged therapy in Phase 1/2 trials for Rett syndrome, and NGN-101, a gene therapy candidate in Phase 1/2 trials for CLN5 Batten disease.
| Market Cap | $524.9M | Trading Days | 647 |
| 52W High | 43.66 |
| 52W Low | 15.93 |
| % Off High | −23.91% |
| YTD | 61.26% | 1Y | 53.23% |
| Since incept. (ann.) | 35.32% |
| Ann. Volatility (1Y) | 83.55% | Ann. Volatility (3Y) | 106.41% |
| Sharpe (1Y) | 0.93 | Sharpe (3Y) | 0.83 |
| Max Drawdown (1Y) | −52.37% | Max Drawdown (3Y) | −89.74% |
| Beta (3Y, vs SPY) | 1.89 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | $525.7M | — |
| STTK | Shattuck Labs, Inc. | $523.0M | — |
| MPLT | MapLight Therapeutics, Inc. | $522.4M | — |
| ARVN | ARVINAS, INC. | $529.1M | — |
| VSTM | Verastem, Inc. | $547.5M | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $548.6M | — |
| SPRY | ARS Pharmaceuticals, Inc. | $563.0M | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $575.2M | 7.2 |
| CRMD | CorMedix Inc. | $576.6M | 3.6 |
| GYRE | GYRE THERAPEUTICS, INC. | $581.2M | 58.8 |
| ALT | Altimmune, Inc. | $581.5M | — |
| Rezolute, Inc. |
| $473.8M |
| — |
